On Wednesday, FMC Corp (NYSE:FMC)’s shares declined -2.67% to $53.54.
FMC Corp (FMC) released its fourth annual Sustainability Report, summarizing the specialty company’s ongoing efforts to address several major global challenges in 2014. The report, “Embracing Opportunities for Tomorrow,” focuses on FMC’s five sustainability priorities: fostering safety, empowering talent, growing innovation, minding our resources, and cultivating community.
FMC integrates sustainability into its businesses by continually seeking ways to apply our advanced technologies, innovative products and scientific capabilities to assist make the world a better place recently, tomorrow and in the future. Products comprise those designed to meet the food and nutrient needs of a growing world population and address climate change through energy storage and lighter weight materials for aircraft manufacturers.
FMC is working to positively influence the following global challenges:
- environmental consciousness for the growing desire for increasingly safe and environmentally benign materials;
- food and health expectations to address the growing population needs, counting accessible healthcare and more nutritious foods;
- land competition requiring raised agricultural efficiency to produce crops, biofuels, biotextiles, and bioplastics;
- climate change to cope with greenhouse gas and other emissions; and
- scarce resources for a growing population’s increasing demand for energy, water and other basic resources.
FMC Corporation, a diversified chemical company, provides solutions, applications, and products for the agricultural, consumer, and industrial markets in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through three segments: FMC Agricultural Solutions, FMC Health and Nutrition, and FMC Lithium. The FMC Agricultural Solutions segment develops, manufactures, and sells crop protection, professional pest control, and lawn and garden products, such as insecticides, herbicides, and fungicides.
Dicks Sporting Goods Inc (NYSE:DKS)’s shares dropped -1.33% to $52.15.
Deutsche Bank Analyst Mike Baker said that the outlook for Dicks Sporting Goods (DKS) is a highlight in an otherwise dismal retail sales climate. Since February, retail sales grew just 2.8 percent, contrast with a 3.8 percent growth last year. This puts “retail on pace for the weakest enhance since the recession year of 2009.”
Yet despite this challenged climate, sporting goods sales have raised around 5.8 percent - up from just 0.2 percent growth at this point last year and the fastest pace since 2012. “Sporting goods is one of the few retail categories to be performing better this year as compared to last year,” the note said.
Specifically, golf seems to be having resurgence. After two years of declines in 2013 and 2014, U.S. golf rounds through April gained 2.2 percent.
According to Baker, this faster growth will assist Dicks Sporting Goods post strong Q2 sales. The analyst reaffirmed Deutsche Bank’s Buy rating and $63 price target. That price target reflects roughly 17 percent upside from current prices.
Dick’s Sporting Goods, Inc. operates as a sporting goods retailer primarily in the eastern United States. The company provides hardlines, counting sporting goods equipment, fitness equipment, golf equipment, and hunting and fishing gear products; apparel; and footwear products and accessories.
At the end of Wednesday’s trade, CTI BioPharma Corp (NASDAQ:CTIC)‘s shares dipped -3.95% to $2.19.
CTI BioPharma Corp (CTIC) declared that it has amended its existing loa contract with Hercules Technology Growth Capital, Inc. (Hercules). Following the amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million under the facility, inclusive of amounts outstanding right away prior to closing of the amendment. On June 9, 2015, about $6.2 million (less fees and expenses) was funded, thereby resulting in a current outstanding principal balance under the facility of $20.0 million. The remaining $5.0 million is accessible for borrowing at CTI BioPharma’s option through June 30, 2016, subject to no event of default under the facility and the satisfaction of the following two conditions: (1) receipt by Hercules on or prior to December 31, 2015 of satisfactory evidence that CTI BioPharma has achieved full patient enrollment for the PERSIST-2 Phase III clinical trial for pacritinib and (2) receipt by Hercules on or prior to June 30, 2016 of satisfactory evidence that CTI BioPharma has achieved positive phase III data in connection with such clinical trial. In connection with the amendment, CTI BioPharma issued Hercules a warrant exercisable in whole or in part for up to 292,398 shares of common stock of CTI BioPharma at any time prior to June 9, 2020 at an initial exercise price per share of $1.71. CTI BioPharma intends to use any future proceeds from any future cash exercise of the warrant for general corporate purposes.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.
TD Ameritrade Holding Corp. (NYSE:AMTD), ended its Wednesday’s trading session with -0.05% loss, and closed at $37.61.
To assist independent registered investment advisors (“RIAs”) keep pace in an era of accelerating technology change, TD Ameritrade Institutional1 has pursued a unique strategy of collaboration, harnessing the innovative and cutting-edge work of an entire community of technology leaders through its Veo Open Access vendor network.
To encourage further partnership and innovation, TD Ameritrade Institutional declares its second-annual Veo® Integrated Awards, recognizing technology companies that are maximizing the capabilities of TD Ameritrade’s Veo Open AccessSM platform and delivering solutions that assist independent RIAs run more productive and efficient businesses. This year’s winners are:
- Innovation Award: Jemstep (Online Advice Solutions)
- Advisor Satisfaction Award: MoneyGuidePro (Financial Planning)
- Newcomer of the Year Award: Advyzon (Portfolio Administration)
The Innovation Award winner was based on several criteria, counting the depth of a product’s integration with Veo, integration with other third-party applications and the scope of adoption by advisors. The Newcomer of the Year Award recognized the firm that achieved the highest levels of integration and went live on Veo in 2014. The winners of these two awards were chosen by a committee of TD Ameritrade Institutional associates, whose methodology was reviewed by Joel Bruckenstein, CFP®, an industry consultant, columnist and co-founder of Technology Tools for Recently.
TD Ameritrade Holding Corporation provides securities brokerage services and related technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. Its products and services comprise tdameritrade.com, a Web platform for self-directed retail investors; Trade Architect, a Web-based platform that enables active investors and traders identify opportunities and stay informed; thinkorswim, a desktop platform for trading; and TD Ameritrade Mobile, which allows on-the-go investors and traders to trade and monitor accounts from Web-enabled mobile devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
